ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1045

The Coll2-1 Peptide of Collagen Type II: A New Actor of Synovitis in Osteoarthritis

Cécile Lambert1, Didier Borderie2, Jean-Emile Dubuc3, François Rannou2 and Yves Henrotin4,5, 1Bone and Cartilage Research Unit, University of Liege, Liege, Belgium, 2Inserm umr 1124, Laboratory of pharmacology, toxicology and cell signaling, University Paris Descartes, Paris, France, 3Orthopaedic Department, University Clinics St Luc, Brussels, Belgium, 4Physical Therapy and Rehabilitation, Princess Paola Hospital, Marche-en-Famenne, Belgium, 5Bone and Cartilage Research Unit, University of Liege, Liège, Belgium

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Collagen, inflammation and osteoarthritis, Synovial Immune Biology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Osteoarthritis and Joint Biology – Basic Science Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

We evaluated the inflammatory effect of Coll2-1 peptide in osteoarthritic synoviocytes and rats by comparing peptide-induced inflammatory reaction with the one induced by bovine type II collagen or streptococcal cell wall.

Methods:

Human synoviocytes from knee OA patients (n=10) were pre-treated with AS0619 or CLI-095 (500nM, 1 and 2.5µM) before a 24 hours treatment with Coll2-1 peptide (108HRGYPGLDG116; 0.45 or 4.5nmol). Expression of Interleukin (IL)-8, Vascular Endothelium Growth Factor (VEGF) and phosphorylation of the IkB-a and p65 were evaluated. Either Coll2-1 peptide, bovine type II collagen (CIA), streptococcal cell wall (SCW) or saline solution (100μl SC or 50μl IA) were injected into Lewis rats (n = 108). The Coll2-1 peptide was injected subcutaneously (SC; 20 and 200μg/100μl/animal) or intra-articular (IA; 0.5 and 5μg/50μl/animal). The bovine type II collagen was SC injected (200μg/100μl/animal), streptococcal cell wall in IA (5μg/50μl/animal). The animals were injected on day 10 and monitored for 21 or 28 days. Visual evaluation of the severity of arthritis and histological lesions were performed.

Results:

Coll2-1 at 0.45 nmol (**P<0.01) and 4.5 nmol (*P<0.05) significantly increased IL-8 gene expression and tended to increase VEGF expression by synoviocytes. With AS0619, a specific antiserum for Coll2-1 peptide, IL-8 expression significantly decreased (*P<0.05). Coll2-1 also induced both translocation of p65 and IkBa degradation. The latter being reduced with oxidative stress inhibitors. With CLI-095, we observed a decrease of IL-8 expression. In vivo, bovine type II collagen injection and Coll2-1 peptide injection resulted in an increase in visual arthritis score from D7. The global histological score was also increased by bovine type II collagen on D21 (p=0.0005) and on D28 (p<0.0001) and by the peptide Coll2-1 on D21 at the concentration of 200μg (p=0.0252) and on D28 at the concentration of 20μg (p=0.0025). Compared to control, all the components of the histological score were similarly modified by bovine type II collagen and the peptide Coll2-1 at both on D21 and on D28: increase in the inflammatory parameter (D21 200μg p=0.0217 and D28 20μg p=0.0021), reduction of proteoglycan contents (D28 200μg p=0.0072 and 20μg p=0.0024), increased cartilage degradation (J28 200μg p=0.0070 and 20μg p=0.0024) and modification of the subchondral bone (D21 200μg p=0.0025 and D28 20μg p=0.0065). Similarly, both the injection of SCW and that of Coll2-1 peptide induced an increase in the visual score from D10. The effect of Coll2-1 peptide on this score was identical to that of the SCW. Compared to control, SCW and Coll2-1 peptide increased the global histological score (D21 p=0.0119 and D28 p=0.0045). Like SCW, the injection of Coll2-1 peptide caused both inflammatory reaction, loss of proteoglycan, appearance of cartilage structural lesions (D28 0.5μg p=0.0201) and subchondral bone modification.

Conclusion:

Coll2-1 peptide is able to induce an inflammatory reaction and structural changes. Coll2-1 may initiate nonspecific natural immunity and therefore be a therapeutic target for biotherapy.


Disclosure: C. Lambert, None; D. Borderie, None; J. E. Dubuc, None; F. Rannou, None; Y. Henrotin, Fidia -Artialis, 1, 5, 8.

To cite this abstract in AMA style:

Lambert C, Borderie D, Dubuc JE, Rannou F, Henrotin Y. The Coll2-1 Peptide of Collagen Type II: A New Actor of Synovitis in Osteoarthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-coll2-1-peptide-of-collagen-type-ii-a-new-actor-of-synovitis-in-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-coll2-1-peptide-of-collagen-type-ii-a-new-actor-of-synovitis-in-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology